Stalman, EW, Wieske, L, van Dam, KPJ, Kummer, LY, van Kempen, ZLE, Killestein, J, Volkers, AG, Tas, SW, Boekel, L, Wolbink, GJ, Van der Kooi, AJ, Raaphorst, J, Lowenberg, M, Takkenberg, RB, D'Haens, GRAM, Spuls, PI, Bekkenk, MW, Musters, AH, Post, NF, Bosma, AL, Hilhorst, ML, Vegting, Y, Bemelman, FJ, Voskuyl, AE, Broens, B, Sanchez, AP, van Els, CACM, De Wit, J, Rutgers, A, de Leeuw, K, Horvath, B, Verschuuren, JJGM, Ruiter, AM, van Ouwerkerk, L, van der Woude, D, Allaart, CF, Teng, OYK
, van Paassen, P, Busch, MH, Jallah, PBP, Brusse, E, van Doorn, PA, Baars, AE, Hijnen, DJ, Schreurs, CRG, Van der Pol, WL, Goedee, HS, Steenhuis, M, Keijzer, S, Keijser, JBD, T2B! immunity against SARS-CoV-2 study group & Eftimov, F 2022, '
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases',
Annals of the Rheumatic Diseases, vol. 81, no. 12, pp. 1757-1766.
https://doi.org/10.1136/ard-2022-222904